Trial Profile
Open-Label Study to Evaluate the Safety and Pharmacokinetics of Single- and Multiple-Dose Extended-Release OROS Paliperidone in Pediatric Subjects (=10 to =17 Years of Age) With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Apr 2010
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 02 Dec 2008 New trial record.